How Much Does Dayvigo (Lemborexant) Cost in Oregon in 2026?

Oregon Retail Pricing for Dayvigo in 2026

The average cash-pay price for a 30-day supply of Dayvigo across Oregon retail pharmacies sits at roughly $85 per month in 2026. That figure reflects negotiated rates at chain and independent pharmacies and stands significantly below Eisai's $320 wholesale acquisition cost 1. Pricing varies by pharmacy location, so patients in Portland metro may see different quotes than those in Bend or Eugene.

Why the Gap Between List Price and Cash Price?

Manufacturer list prices reflect pre-rebate costs. Pharmacy benefit managers negotiate discounts, and GoodRx-style discount programs compress the retail sticker further. The FDA-approved label specifies two dose strengths, 5 mg and 10 mg, but both typically carry the same per-tablet retail price 1. Patients without insurance should request a price comparison across at least three Oregon pharmacies before filling.

Comparing Dayvigo to Other Insomnia Medications

Generic suvorexant (Belsomra) is not yet available; suvorexant's patent protections run into 2029. Generic zolpidem costs $5 to $15 per month, but its mechanism differs. Lemborexant blocks both orexin-1 and orexin-2 receptors, a dual-receptor approach shown in SUNRISE-1 (N=1,006) to improve sleep onset latency by a mean 11.6 minutes versus placebo at the 10 mg dose 2. For patients who have failed or cannot tolerate GABA-A modulators, DORAs fill a distinct pharmacologic niche per the American Academy of Sleep Medicine's 2023 clinical practice guideline 3.

Oregon Medicaid Coverage for Dayvigo

Oregon Medicaid (Oregon Health Plan) covers Dayvigo with prior authorization. The prior authorization requirement means prescribers must document that the patient meets specific criteria, typically a trial and failure of at least one first-line generic sleep agent such as trazodone, doxepin, or generic zolpidem 4.

How to Manage Prior Authorization

Clinicians submit a PA request to the Oregon Health Authority's pharmacy unit. Turnaround is typically 24 to 72 hours. Documentation should include the diagnosis (chronic insomnia disorder per DSM-5 or ICSD-3 criteria), prior medication trials with dates and reasons for discontinuation, and confirmation that non-pharmacologic interventions like cognitive behavioral therapy for insomnia (CBT-I) have been considered. The AASM strongly recommends CBT-I as first-line treatment 3, and payers increasingly require documentation of its use or contraindication.

What Happens If PA Is Denied?

Patients can appeal through Oregon's standard Medicaid grievance process. An alternative is switching to suvorexant (Belsomra), which may sit on a different formulary tier. Both are DORAs; SUNRISE-2 (N=949) demonstrated that lemborexant 5 mg and 10 mg maintained efficacy over 12 months without evidence of rebound insomnia upon discontinuation 5, data that may support a PA appeal when shorter-acting agents have caused next-day impairment.

Commercial Insurance Coverage in Oregon

Most major commercial plans in Oregon, including Providence Health Plan, Moda Health, PacificSource, and Regence BlueCross BlueShield, list Dayvigo on specialty or non-preferred brand tiers. That means patients face copays ranging from $30 to $75 per month after meeting their deductible, depending on plan design 1.

Step Therapy Requirements

Many commercial plans require step therapy. A 2022 analysis published in the Journal of Clinical Sleep Medicine found that 68% of commercial formularies imposed step edits on DORAs, typically requiring failure of a generic hypnotic before approval 6. Prescribers can expedite this by documenting prior medication history directly in the electronic PA submission.

Employer-Sponsored Plans

Self-funded employer plans in Oregon set their own formulary rules. Large employers like Nike, Intel, and OHSU may offer more favorable DORA coverage. Employees should check their specific Summary of Benefits and Coverage document or call the number on their pharmacy card.

The Eisai Savings Card: How It Works in Oregon

Eisai offers a copay savings program for commercially insured patients. Eligible patients can pay as little as $0 out of pocket per fill, with Eisai covering up to a defined annual maximum (typically $3,600 per year). The card cannot be used with Medicare, Medicaid, Tricare, or other federal programs per the federal Anti-Kickback Statute 7.

Eligibility Requirements

Patients must hold commercial or private insurance, be residents of the United States (Oregon qualifies), and have a valid prescription for Dayvigo. The card applies at participating pharmacies, which includes most Oregon retail chains. Enrollment is available online through Eisai's patient support portal or through prescriber enrollment at the point of care.

Limitations to Know

The savings card does not lower the pharmacy's acquisition cost. It subsidizes the patient's copay. If a plan excludes Dayvigo entirely (not just non-preferred, but excluded), the card typically cannot override that exclusion. Patients in this situation may need a formulary exception request, supported by clinical documentation of DORA-specific need.

Compounded Lemborexant in Oregon

Licensed 503A compounding pharmacies in Oregon can prepare lemborexant formulations. Under federal law, 503A pharmacies compound in response to individual prescriptions and must comply with United States Pharmacopeia (USP) standards for sterility and potency 8. Oregon's Board of Pharmacy regulates these facilities under OAR 855-044.

Is Compounded Lemborexant Legal in Oregon?

Yes. Oregon permits 503A compounding when a prescriber writes a patient-specific prescription. The FDA's DQSA framework allows compounding of commercially available drugs when a prescriber determines a clinical need for a modified formulation (different strength, alternative dosage form, or allergen-free preparation) 8. Patients should verify that their compounding pharmacy holds current Oregon Board of Pharmacy licensure.

Cost Considerations for Compounded Formulations

Compounded lemborexant pricing varies by pharmacy. Some 503A pharmacies advertise zero-dollar programs for qualifying patients. Patients should confirm whether their insurance covers compounded medications, as many commercial plans and Oregon Medicaid exclude compounded products from standard pharmacy benefits.

Telehealth Prescribing of Dayvigo in Oregon

Oregon allows telehealth prescribing of Dayvigo. The Oregon Medical Board permits Schedule IV controlled substance prescribing via telehealth when the prescriber conducts an adequate clinical evaluation 9. Lemborexant is classified as Schedule IV by the DEA, the same classification as zolpidem and suvorexant 10.

How Telehealth Affects Cost

Telehealth visits typically cost $50 to $150 out of pocket for uninsured patients, though most Oregon commercial plans cover telehealth at in-person copay parity under state law. The total cost of Dayvigo via telehealth equals the visit fee plus the medication cost. For patients in rural Oregon counties (Harney, Malheur, Lake), telehealth removes the need for a multi-hour drive to a sleep medicine specialist.

DEA and Prescribing Rules

The DEA's post-pandemic telehealth prescribing flexibilities for controlled substances continue through 2025 under the Temporary Extension framework. For 2026, prescribers should confirm current DEA telemedicine registration requirements. Oregon-licensed prescribers (MDs, DOs, NPs, PAs) may prescribe lemborexant after a synchronous audio-video evaluation 10.

Clinical Efficacy: What Oregon Patients Should Expect

SUNRISE-1 randomized 1,006 adults with insomnia to lemborexant 5 mg, 10 mg, zolpidem ER 6.25 mg, or placebo for one month 2. At the 10 mg dose, lemborexant reduced subjective wake-after-sleep-onset (WASO) by 29.4 minutes versus placebo (P<0.001). The 5 mg dose reduced WASO by 23.5 minutes.

Long-Term Data

SUNRISE-2 followed 949 patients for 12 months on lemborexant 5 mg or 10 mg versus placebo 5. Sleep onset latency improvements persisted through month 12 with no evidence of tolerance. Upon discontinuation, rebound insomnia did not occur at rates statistically different from placebo, a finding that distinguishes DORAs from benzodiazepine receptor agonists 11.

Safety Profile

The most common adverse event in trials was somnolence (reported in 7% at 5 mg, 10% at 10 mg versus 1% placebo). Sleep paralysis occurred in <1% of patients. The FDA label carries no boxed warning, unlike some older sedative-hypnotics 1. A pooled safety analysis of over 1,900 patients found no signal for complex sleep behaviors at rates exceeding placebo 12.

How to Get the Lowest Dayvigo Price in Oregon

Start with the Eisai copay card if commercially insured. If uninsured, compare cash prices at three or more pharmacies using price-comparison tools. Ask your prescriber about 503A compounding if you need a modified formulation. For Oregon Medicaid enrollees, have your prescriber submit PA documentation proactively before sending the prescription to the pharmacy 13.

Step-by-Step Cost Reduction Checklist

1. Confirm your insurance formulary status for Dayvigo (preferred, non-preferred, or excluded).
2. If non-preferred, ask your prescriber to submit PA with documented trial-and-failure of generics.
3. Enroll in the Eisai savings card if commercially insured.
4. If cash-pay, compare prices at Costco, Walmart, Fred Meyer, and independent Oregon pharmacies.
5. Ask about 503A compounded lemborexant for potential additional savings.
6. Consider telehealth if specialist access is limited in your county.

Oregon-Specific Discount and Assistance Programs

Beyond the Eisai manufacturer card, Oregon residents may qualify for NeedyMeds or RxAssist databases that aggregate patient assistance programs 7. Oregon also operates the Prescription Drug Affordability Board, established under HB 2958 (2023), which reviews drug pricing and may issue upper payment limits for high-cost drugs in the future 14.

Community Health Centers

Oregon's federally qualified health centers (FQHCs) access 340B drug pricing, which can reduce acquisition costs by 25% to 50% below wholesale. Patients receiving care at FQHC sites like Virginia Garcia Memorial Health Center or Central City Concern may access Dayvigo at reduced cost through the center's 340B contract pharmacy network.